Ed DeVaney’s promotion is the latest leadership shakeup at CVS Health as the company works on a multi-year turnaround plan.
Argus raised the firm’s price target on CVS Health (CVS) to $77 from $68 and keeps a Buy rating on the shares. Despite an uneven performance ...
In a report released on February 14, Steven Silver from Argus Research maintained a Buy rating on CVS Health (CVS – Research Report). The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results